Company withholds lifesaving drug in row with Australian government over its useBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5869 (Published 26 September 2014) Cite this as: BMJ 2014;349:g5869
- Amy Coopes
A lifesaving drug treatment for the ultra-rare but fatal blood disorder atypical haemolytic uraemic syndrome (aHUS) is at the centre of an unprecedented funding stand-off in Australia that has left patients in limbo and is being closely watched abroad, experts have said.
The condition of aHUS is caused by chronic, uncontrolled activation of the alternative complement pathway and results …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial